Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 5
  5. Article
Volume 21, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Recent studies have found that a link between people with type 1 diabetes mellitus (T1DM) are at higher risk of morbidity as well as mortality from COVID-19 infection, indicating a need for vaccination. T1DM appears to impair innate and adaptive immunity. The overabundance of pro-inflammatory cytokines produced in COVID-19 illness that is severe and potentially fatal is known as a “cytokine storm.” Numerous cohorts have revealed chronic inflammation as a key risk factor for unfavorable COVID-19 outcomes. TNF-α, interleukin (IL)-1a, IL-1, IL-2, IL-6, and other cytokines were found in higher concentrations in patients with T1DM. Even more importantly, oxidative stress contributes significantly to the severity and course of COVID-19's significant role in the progression and severity of COVID-19 diseases. Severe glucose excursions, a defining characteristic of type 1 diabetes, are widely recognized for their potent role as mediating agents of oxidative stress several routes, such as heightened production of advanced glycation end products (AGEs) and activation of protein kinase C (PKC). Furthermore, persistent endothelial dysfunction and hypercoagulation found in T1DM may impair microcirculation and endothelium, which could result in the development of various organ failure and acute breathing syndrome.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998290807240522045553
2024-05-24
2025-01-18

  • From This Site

    /content/journals/cdr/10.2174/0115733998290807240522045553
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HashemiM. Management of environmental health to prevent an outbreak of COVID-19. A review. Environmental and Health Management of Novel Coronavirus Disease (COVID-19).AmsterdamElsevier2021235267
     [Google Scholar]
  2. KoliakiC. TentolourisA. EleftheriadouI. MelidonisA. DimitriadisG. TentolourisN. Clinical management of diabetes mellitus in the era of COVID-19: Practical issues, peculiarities and concerns.J. Clin. Med.202097228810.3390/jcm907228832708504
     [Google Scholar]
  3. VermaA. RajputR. VermaS. BalaniaV.K.B. JangraB. Impact of lockdown in COVID 19 on glycemic control in patients with type 1 Diabetes Mellitus.Diabetes Metab. Syndr.20201451213121610.1016/j.dsx.2020.07.01632679527
     [Google Scholar]
  4. ZhangY. CuiY. ShenM. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study.Diabetes Res. Clin. Pract.202016510822710.1016/j.diabres.2020.10822732446795
     [Google Scholar]
  5. KumarA. AroraA. SharmaP. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis.Diabetes Metab. Syndr.202014453554510.1016/j.dsx.2020.04.04432408118
     [Google Scholar]
  6. LimS. BaeJ.H. KwonH.S. NauckM.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management.Nat. Rev. Endocrinol.2021171113010.1038/s41574‑020‑00435‑433188364
     [Google Scholar]
  7. HolmanN. KnightonP. KarP. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study.Lancet Diabetes Endocrinol.202081082383310.1016/S2213‑8587(20)30271‑032798471
     [Google Scholar]
  8. EbekozienO.A. NoorN. GallagherM.P. AlonsoG.T. Type 1 diabetes and COVID-19: Preliminary findings from a multicenter surveillance study in the US.Diabetes Care2020438e83e8510.2337/dc20‑108832503837
     [Google Scholar]
  9. BrufskyA. Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemic.J. Med. Virol.202092777077510.1002/jmv.2588732293710
     [Google Scholar]
  10. YangJ.K. FengY. YuanM.Y. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.Diabet. Med.200623662362810.1111/j.1464‑5491.2006.01861.x16759303
     [Google Scholar]
  11. BarronE. BakhaiC. KarP. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study.Lancet Diabetes Endocrinol.202081081382210.1016/S2213‑8587(20)30272‑232798472
     [Google Scholar]
  12. DiMeglioL.A. COVID-19 and children with diabetes-updates, unknowns, and next steps: First, do no extrapolation.Diabetes Care2020431126312634
     [Google Scholar]
  13. d’AnnunzioG. MaffeisC. CherubiniV. Caring for children and adolescents with type 1 diabetes mellitus: Italian Society for Pediatric Endocrinology and Diabetology (ISPED) statements during COVID-19 pandemia.Diabetes Res. Clin. Pract.202016810837210.1016/j.diabres.2020.10837232827594
     [Google Scholar]
  14. TittelS.R. RosenbauerJ. KamrathC. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany?Diabetes Care20204311e172e17310.2337/dc20‑163332826282
     [Google Scholar]
  15. KountouriA. KorakasE. IkonomidisI. Type 1 diabetes mellitus in the SARS-CoV-2 pandemic: Oxidative stress as a major patho-physiological mechanism linked to adverse clinical outcomes.Antioxidants202110575210.3390/antiox1005075234065123
     [Google Scholar]
  16. CastañoL. EisenbarthG.S. Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat.Annu. Rev. Immunol.19908164767910.1146/annurev.iy.08.040190.0032432188676
     [Google Scholar]
  17. LedermanM.M. SchiffmanG. RodmanH.M. Pneumococcal immunization in adult diabetics.Diabetes198130211912110.2337/diab.30.2.1197202857
     [Google Scholar]
  18. PozzilliP. GaleE.A.M. VisallilN. The immune response to influenza vaccination in diabetic patients.Diabetologia1986291285085410.1007/BF008701393569690
     [Google Scholar]
  19. ValleA. GiamporcaroG.M. ScaviniM. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes.Diabetes20136262072207710.2337/db12‑134523349491
     [Google Scholar]
  20. JacksonM.H. CollierA. NicollJ.J. Neutrophil count and activation in vascular disease.Scott. Med. J.1992372414310.1177/0036933092037002051609264
     [Google Scholar]
  21. MarhofferW. SteinM. SchleinkoferL. FederlinK. Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus.Diabetes Res. Clin. Pract.199319318318810.1016/0168‑8227(93)90112‑I8319516
     [Google Scholar]
  22. DelamaireM. MaugendreD. MorenoM. Le GoffM.C. AllannicH. GenetetB. Exploration of the various steps of polymorphonuclear neutrophil function in diabetic patients.J. Mal. Vasc.19952021071127650435
     [Google Scholar]
  23. MeradM. MartinJ.C. Author Correction: Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages.Nat. Rev. Immunol.202020744810.1038/s41577‑020‑0353‑y32488203
     [Google Scholar]
  24. WangJ.Z. ZhangR.Y. BaiJ. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients.Int. J. Cardiol.202031213713810.1016/j.ijcard.2020.04.00932321655
     [Google Scholar]
  25. BarnesB.J. AdroverJ.M. Baxter-StoltzfusA. Targeting potential drivers of COVID-19: Neutrophil extracellular traps.J. Exp. Med.20202176e2020065210.1084/jem.2020065232302401
     [Google Scholar]
  26. BrinkmannV. ZychlinskyA. Neutrophil extracellular traps: Is immunity the second function of chromatin?J. Cell Biol.2012198577378310.1083/jcb.20120317022945932
     [Google Scholar]
  27. WangY. XiaoY. ZhongL. Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with β-cell autoimmunity in patients with type 1 diabetes.Diabetes201463124239424810.2337/db14‑048025092677
     [Google Scholar]
  28. QinJ. FuS. SpeakeC. GreenbaumC.J. OdegardJ.M. NETosis-associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count.Clin. Exp. Immunol.2016184331832210.1111/cei.1278326939803
     [Google Scholar]
  29. RiyapaD. BuddhisaS. KorbsrisateS. Neutrophil extracellular traps exhibit antibacterial activity against burkholderia pseudomallei and are influenced by bacterial and host factors.Infect. Immun.201280113921392910.1128/IAI.00806‑1222927051
     [Google Scholar]
  30. JoshiM.B. LadA. Bharath PrasadA.S. BalakrishnanA. RamachandraL. SatyamoorthyK. High glucose modulates IL‐6 mediated immune homeostasis through impeding neutrophil extracellular trap formation.FEBS Lett.2013587142241224610.1016/j.febslet.2013.05.05323735697
     [Google Scholar]
  31. LiY. LiuY. ChuC-Q. Th17 cells in type 1 diabetes: Role in the pathogenesis and regulation by gut microbiome.Mediators Inflamm.2015201563847010.1155/2015/638470
     [Google Scholar]
  32. BradshawE.M. RaddassiK. ElyamanW. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cy-tokines inducing Th17 cells.J. Immunol.200918374432443910.4049/jimmunol.090057619748982
     [Google Scholar]
  33. KaizerE.C. GlaserC.L. ChaussabelD. BanchereauJ. PascualV. WhiteP.C. Gene expression in peripheral blood mononuclear cells from children with diabetes.J. Clin. Endocrinol. Metab.20079293705371110.1210/jc.2007‑097917595242
     [Google Scholar]
  34. Menart-HoutermansB. RütterR. NowotnyB. Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: Results from the German Diabetes Study (GDS).Diabetes Care20143782326233310.2337/dc14‑031625061140
     [Google Scholar]
  35. LongS.A. BucknerJ.H. CD4+FOXP3+ T regulatory cells in human autoimmunity: More than a numbers game.J. Immunol.201118752061206610.4049/jimmunol.100322421856944
     [Google Scholar]
  36. KukrejaA. CostG. MarkerJ. Multiple immuno-regulatory defects in type-1 diabetes.J. Clin. Invest.2002109113114010.1172/JCI021360511781358
     [Google Scholar]
  37. HuangI. LimM.A. PranataR. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression.Diabetes Metab. Syndr.202014439540310.1016/j.dsx.2020.04.01832334395
     [Google Scholar]
  38. ChenY. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: A systematic review and meta-analysis.MedRxiv202010.1101/2020.03.25.20043133
     [Google Scholar]
  39. PambiancoG. CostacouT. OrchardT.J. The prediction of major outcomes of type 1 diabetes: A 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: The Pittsburgh Epidemiology of Diabetes Complications Study experience.Diabetes Care20073051248125410.2337/dc06‑205317303788
     [Google Scholar]
  40. PriyaG. KalraS. A review of insulin resistance in type 1 diabetes: Is there a place for adjunctive metformin?Diabetes Ther.20189134936110.1007/s13300‑017‑0333‑929139080
     [Google Scholar]
  41. KaulK. ApostolopoulouM. RodenM. Insulin resistance in type 1 diabetes mellitus.Metabolism201564121629163910.1016/j.metabol.2015.09.00226455399
     [Google Scholar]
  42. NishidaK. OtsuK. Inflammation and metabolic cardiomyopathy.Cardiovasc. Res.2017113438939810.1093/cvr/cvx01228395010
     [Google Scholar]
  43. PanX. KamingaA.C. WenS.W. AcheampongK. LiuA. Omentin-1 in diabetes mellitus: A systematic review and meta-analysis.PLoS One20191412e022629210.1371/journal.pone.022629231821362
     [Google Scholar]
  44. LucK. Schramm-LucA. GuzikT.J. MikolajczykT.P. Oxidative stress and inflammatory markers in prediabetes and diabetes.J. Physiol. Pharmacol.201970632084643
     [Google Scholar]
  45. DominguetiC.P. DusseL.M.S.A. CarvalhoM.G. de SousaL.P. GomesK.B. FernandesA.P. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications.J. Diabetes Complications201630473874510.1016/j.jdiacomp.2015.12.01826781070
     [Google Scholar]
  46. GoudaW. MageedL. Abd El DayemS.M. AshourE. AfifyM. Evaluation of pro-inflammatory and anti-inflammatory cytokines in type 1 diabetes mellitus.Bull. Natl. Res. Cent.20184211410.1186/s42269‑018‑0016‑3
     [Google Scholar]
  47. DoganY. MathML Namespace.2006Available From: http://www.w3.org/1998/Math/MathML
  48. TalaatI.M. NasrA. AlsulaimaniA.A. Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin D in children with type 1 diabetes.J. Endocrinol. Invest.201639121425143410.1007/s40618‑016‑0514‑927541155
     [Google Scholar]
  49. UrurahyM.A.G. LoureiroM.B. Freire-NetoF.P. Increased TLR2 expression in patients with type 1 diabetes: Evidenced risk of microalbuminuria.Pediatr. Diabetes201213214715410.1111/j.1399‑5448.2011.00794.x21848584
     [Google Scholar]
  50. HuntK.J. BakerN.L. ClearyP.A. KleinR. VirellaG. Lopes-VirellaM.F. Longitudinal association between endothelial dysfunction, inflam-mation, and clotting biomarkers with subclinical atherosclerosis in Type 1 Diabetes: An evaluation of the DCCT/EDIC cohort.Diabetes Care20153871281128910.2337/dc14‑287725852210
     [Google Scholar]
  51. DevarajS. GlaserN. GriffenS. Wang-PolagrutoJ. MiguelinoE. JialalI. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes.Diabetes200655377477910.2337/diabetes.55.03.06.db05‑141716505242
     [Google Scholar]
  52. WuC. ChenX. CaiY. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus dis-ease 2019 pneumonia in Wuhan, China.JAMA Intern. Med.2020180793494310.1001/jamainternmed.2020.099432167524
     [Google Scholar]
  53. MehtaP. McAuleyD.F. BrownM. SanchezE. TattersallR.S. MansonJ.J. COVID-19: Consider cytokine storm syndromes and immunosup-pression.Lancet2020395102291033103410.1016/S0140‑6736(20)30628‑032192578
     [Google Scholar]
  54. BrownleeM. Biochemistry and molecular cell biology of diabetic complications.Nature2001414686581382010.1038/414813a11742414
     [Google Scholar]
  55. Delgado-RocheL. MestaF. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection.Arch. Med. Res.202051538438710.1016/j.arcmed.2020.04.01932402576
     [Google Scholar]
  56. FatimaN. FaisalS.M. ZubairS. Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: Correlation with age and glycemic condition in diabetic human subjects.PLoS One2016118e016154810.1371/journal.pone.016154827575603
     [Google Scholar]
  57. FiroozraiM. NourbakhshM. Razzaghy-AzarM. Erythrocyte susceptibility to oxidative stress and antioxidant status in patients with type 1 diabetes.Diabetes Res. Clin. Pract.200777342743210.1016/j.diabres.2007.02.00117360068
     [Google Scholar]
  58. GleisnerA. MartinezL. PinoR. Oxidative stress markers in plasma and urine of prepubertal patients with type 1 diabetes mellitus.J. Pediatr. Endocrinol. Metab.2006198995100010.1515/JPEM.2006.19.8.99516995584
     [Google Scholar]
  59. RincónJ. CorreiaD. ArcayaJ.L. Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension.Life Sci.2015124819010.1016/j.lfs.2015.01.00525623850
     [Google Scholar]
  60. Beltrán-GarcíaJ. Osca-VerdegalR. PallardóF.V. Oxidative stress and inflammation in COVID-19-associated sepsis: The potential role of anti-oxidant therapy in avoiding disease progression.Antioxidants202091093610.3390/antiox910093633003552
     [Google Scholar]
  61. CecchiniR. CecchiniA.L. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression.Med. Hypotheses202014311010210.1016/j.mehy.2020.11010232721799
     [Google Scholar]
  62. NanduriJ. YuanG. KumarG.K. SemenzaG.L. PrabhakarN.R. Transcriptional responses to intermittent hypoxia.Respir. Physiol. Neurobiol.20081641-227728110.1016/j.resp.2008.07.00618692603
     [Google Scholar]
  63. CavezziA. TroianiE. CorraoS. COVID-19: Hemoglobin, iron, and hypoxia beyond inflammation. A narrative review.Clin. Pract.2020102127110.4081/cp.2020.127132509258
     [Google Scholar]
  64. SchechterA.N. GladwinM.T. Hemoglobin and the paracrine and endocrine functions of nitric oxide.N. Engl. J. Med.2003348151483148510.1056/NEJMcibr02304512686706
     [Google Scholar]
  65. FurchgottR.F. ZawadzkiJ.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.Nature1980288578937337610.1038/288373a0
     [Google Scholar]
  66. DeanfieldJ.E. HalcoxJ.P. RabelinkT.J. Endothelial function and dysfunction: Testing and clinical relevance.Circulation2007115101285129510.1161/CIRCULATIONAHA.106.65285917353456
     [Google Scholar]
  67. MachnicaL. DejaG. PolanskaJ. Blood pressure disturbances and endothelial dysfunction markers in children and adolescents with type 1 diabetes.Atherosclerosis2014237112913410.1016/j.atherosclerosis.2014.09.00625238220
     [Google Scholar]
  68. PerrinR.M. HarperS.J. BatesD.O. A role for the endothelial glycocalyx in regulating microvascular permeability in diabetes mellitus.Cell Biochem. Biophys.2007492657210.1007/s12013‑007‑0041‑617906361
     [Google Scholar]
  69. OnatD. BrillonD. ColomboP.C. SchmidtA.M. Human vascular endothelial cells: A model system for studying vascular inflammation in diabetes and atherosclerosis.Curr. Diab. Rep.201111319320210.1007/s11892‑011‑0182‑221337131
     [Google Scholar]
  70. LemkesB.A. NieuwdorpM. HoekstraJ.B.L. HollemanF. The glycocalyx and cardiovascular disease in diabetes: Should we judge the endothelium by its cover?Diabetes Technol. Ther.201214S1Suppl. 1S-3S-1010.1089/dia.2012.001122650222
     [Google Scholar]
  71. NieuwdorpM. van HaeftenT.W. GouverneurM.C.L.G. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.Diabetes200655248048610.2337/diabetes.55.02.06.db05‑110316443784
     [Google Scholar]
  72. GianniniC. MohnA. ChiarelliF. KelnarC.J.H. Macrovascular angiopathy in children and adolescents with type 1 diabetes.Diabetes Metab. Res. Rev.201127543646010.1002/dmrr.119521433262
     [Google Scholar]
  73. KesslerL. WieselM.L. AttaliP. MossardJ.M. CazenaveJ.P. PingetM. Von Willebrand factor in diabetic angiopathy.Diabetes Metab.19982443273369805643
     [Google Scholar]
  74. MargeticS. Inflammation and haemostasis.Biochem. Med. (Zagreb)20122214962
     [Google Scholar]
  75. WautierJ.L. GuillausseauP.J. Diabetes, advanced glycation endproducts and vascular disease.Vasc. Med.19983213113710.1177/1358836X98003002079796076
     [Google Scholar]
  76. YamagishiS. MatsuiT. Advanced glycation end products, oxidative stress and diabetic nephropathy.Oxid. Med. Cell. Longev.20103210110810.4161/oxim.3.2.1114820716934
     [Google Scholar]
  77. SenaC.M. PereiraA.M. SeiçaR. Endothelial dysfunction — A major mediator of diabetic vascular disease.Biochim. Biophys. Acta Mol. Basis Dis.20131832122216223110.1016/j.bbadis.2013.08.00623994612
     [Google Scholar]
  78. HeL. Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS.J. Pathol.20062103288297
     [Google Scholar]
  79. VargaZ. FlammerA.J. SteigerP. Endothelial cell infection and endotheliitis in COVID-19.Lancet2020395102341417141810.1016/S0140‑6736(20)30937‑532325026
     [Google Scholar]
  80. SuH. YangM. WanC. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.Kidney Int.202098121922710.1016/j.kint.2020.04.00332327202
     [Google Scholar]
  81. CopinM.C. ParmentierE. DuburcqT. PoissyJ. MathieuD. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection.Intensive Care Med.20204661124112610.1007/s00134‑020‑06057‑832328726
     [Google Scholar]
  82. MorelO. Prothrombotic changes in diabetes mellitus.Semin. Thromb. Hemost.2013395477488
     [Google Scholar]
  83. WinocourP.D. WatalaC. PerryD.W. Kinlough-RathboneR.L. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins.Thromb. Haemost.199268557758210.1055/s‑0038‑16463201455404
     [Google Scholar]
  84. AssertR. ScherkG. BumbureA. PiragsV. SchatzH. PfeifferA.F.H. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro.Diabetologia200144218819510.1007/s00125005159811270675
     [Google Scholar]
  85. SchaefferG. WascherT.C. KostnerG.M. GraierW.F. Alterations in platelet Ca 2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production.Diabetologia199942216717610.1007/s00125005113510064096
     [Google Scholar]
  86. ZhouF. YuT. DuR. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study.Lancet2020395102291054106210.1016/S0140‑6736(20)30566‑332171076
     [Google Scholar]
  87. BornsteinS.R. RubinoF. KhuntiK. Practical recommendations for the management of diabetes in patients with COVID-19.Lancet Diabetes Endocrinol.20208654655010.1016/S2213‑8587(20)30152‑232334646
     [Google Scholar]
  88. BindomS.M. LazartiguesE. The sweeter side of ACE2: Physiological evidence for a role in diabetes.Mol. Cell. Endocrinol.2009302219320210.1016/j.mce.2008.09.02018948167
     [Google Scholar]
  89. Roca-HoH. RieraM. PalauV. PascualJ. SolerM. Characterization of ACE and ACE2 expression within different organs of the NOD mouse.Int. J. Mol. Sci.201718356310.3390/ijms1803056328273875
     [Google Scholar]
  90. MonteilV. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.Cell20201814905913
     [Google Scholar]
  91. YuM.G. KeenanH.A. ShahH.S. Residual β cell function and monogenic variants in long-duration type 1 diabetes patients.J. Clin. Invest.201912983252326310.1172/JCI12739731264968
     [Google Scholar]
  92. LiJ. WangX. ChenJ. ZuoX. ZhangH. DengA. COVID ‐19 infection may cause ketosis and ketoacidosis.Diabetes Obes. Metab.202022101935194110.1111/dom.1405732314455
     [Google Scholar]
  93. RabboneI. SchiaffiniR. CherubiniV. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children?Diabetes Care202043112870287210.2337/dc20‑132132778554
     [Google Scholar]
  94. KamrathC. MönkemöllerK. BiesterT. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany.JAMA2020324880180410.1001/jama.2020.1344532702751
     [Google Scholar]
  95. YangJ.K. LinS.S. JiX.J. GuoL.M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes.Acta Diabetol.201047319319910.1007/s00592‑009‑0109‑419333547
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998290807240522045553
Loading
Risk of Type 1 Diabetes Mellitus in SARS-CoV-2 Patients
Curr. Diabetes Rev. 21, E240524230298 (2025); https://doi.org/10.2174/0115733998290807240522045553
/content/journals/cdr/10.2174/0115733998290807240522045553
/content/journals/cdr/10.2174/0115733998290807240522045553
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): coagulopathy; COVID-19; Inflammation; oxidative stress; SARS-CoV-2; type 1 diabetes

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test